vs
Side-by-side financial comparison of Dingdong (Cayman) Ltd (DDL) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $115.3M, roughly 1.8× Dingdong (Cayman) Ltd). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 5.8%, a 51.6% gap on every dollar of revenue.
Dingdong (Cayman) Ltd operates a leading on-demand grocery e-commerce platform primarily serving the Chinese market. It provides fresh produce, daily necessities, ready-to-eat meals, and household staples to urban consumers, leveraging optimized supply chains and localized logistics networks to offer fast, reliable 30-minute delivery services, prioritizing product freshness and user convenience.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
DDL vs IDYA — Head-to-Head
Income Statement — Q3 FY2022 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $115.3M | $207.8M |
| Net Profit | $6.7M | $119.2M |
| Gross Margin | — | — |
| Operating Margin | 5.3% | 52.2% |
| Net Margin | 5.8% | 57.4% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 330.1% |
| EPS (diluted) | $-0.02 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $207.8M | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 | ||
| Q3 22 | $115.3M | $29.7M | ||
| Q2 22 | $136.7M | — | ||
| Q1 22 | $118.5M | — |
| Q3 25 | — | $119.2M | ||
| Q3 24 | — | $-51.8M | ||
| Q2 24 | — | $-52.8M | ||
| Q1 24 | — | $-39.6M | ||
| Q3 22 | $6.7M | $1.6M | ||
| Q2 22 | $717.6K | — | ||
| Q1 22 | $10.4M | — |
| Q3 25 | — | 52.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | 5.3% | 2.2% | ||
| Q2 22 | 0.0% | — | ||
| Q1 22 | 8.2% | — |
| Q3 25 | — | 57.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | 5.8% | 5.4% | ||
| Q2 22 | 0.5% | — | ||
| Q1 22 | 8.8% | — |
| Q3 25 | — | $1.33 | ||
| Q3 24 | — | $-0.60 | ||
| Q2 24 | — | $-0.68 | ||
| Q1 24 | — | $-0.53 | ||
| Q3 22 | $-0.02 | $0.04 | ||
| Q2 22 | $-0.00 | — | ||
| Q1 22 | $-0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $113.7M | $786.9M |
| Total DebtLower is stronger | $135.8K | — |
| Stockholders' EquityBook value | $4.5M | $1.1B |
| Total Assets | $178.3M | $1.2B |
| Debt / EquityLower = less leverage | 0.03× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $786.9M | ||
| Q3 24 | — | $920.0M | ||
| Q2 24 | — | $701.7M | ||
| Q1 24 | — | $698.8M | ||
| Q3 22 | $113.7M | $386.2M | ||
| Q2 22 | $124.9M | — | ||
| Q1 22 | $105.6M | — |
| Q3 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | $135.8K | — | ||
| Q2 22 | $322.0K | — | ||
| Q1 22 | $527.9K | — |
| Q3 25 | — | $1.1B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $931.7M | ||
| Q1 24 | — | $935.3M | ||
| Q3 22 | $4.5M | $368.8M | ||
| Q2 22 | $8.5M | — | ||
| Q1 22 | $5.9M | — |
| Q3 25 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $973.7M | ||
| Q1 24 | — | $961.5M | ||
| Q3 22 | $178.3M | $410.9M | ||
| Q2 22 | $194.3M | — | ||
| Q1 22 | $187.7M | — |
| Q3 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | 0.03× | — | ||
| Q2 22 | 0.04× | — | ||
| Q1 22 | 0.09× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $142.2M |
| Free Cash FlowOCF − Capex | — | $142.2M |
| FCF MarginFCF / Revenue | — | 68.4% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $142.2M | ||
| Q3 24 | — | $-49.2M | ||
| Q2 24 | — | $-32.9M | ||
| Q1 24 | — | $-43.8M | ||
| Q3 22 | — | $-24.2M | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q3 25 | — | $142.2M | ||
| Q3 24 | — | $-49.7M | ||
| Q2 24 | — | $-33.9M | ||
| Q1 24 | — | $-45.1M | ||
| Q3 22 | — | $-25.3M | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q3 25 | — | 68.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | -85.1% | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q3 25 | — | 0.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | 3.7% | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q3 25 | — | 1.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | -14.96× | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
